Free Trial

Biogen (BIIB) Competitors

Biogen logo
$129.99 +4.40 (+3.50%)
Closing price 03:59 PM Eastern
Extended Trading
$128.90 -1.09 (-0.84%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BIIB vs. REGN, ALNY, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, and HALO

Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry.

Biogen vs. Its Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Biogen had 2 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 41 mentions for Biogen and 39 mentions for Regeneron Pharmaceuticals. Biogen's average media sentiment score of 0.99 beat Regeneron Pharmaceuticals' score of 0.81 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regeneron Pharmaceuticals
17 Very Positive mention(s)
5 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Positive
Biogen
21 Very Positive mention(s)
2 Positive mention(s)
15 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Regeneron Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.

Regeneron Pharmaceuticals has a net margin of 31.94% compared to Biogen's net margin of 15.07%. Regeneron Pharmaceuticals' return on equity of 15.27% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals31.94% 15.27% 11.93%
Biogen 15.07%14.03%8.32%

Regeneron Pharmaceuticals presently has a consensus target price of $813.57, suggesting a potential upside of 51.49%. Biogen has a consensus target price of $188.48, suggesting a potential upside of 44.58%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regeneron Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80
Biogen
0 Sell rating(s)
20 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.38

Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$14.20B4.08$4.41B$39.2813.67
Biogen$9.68B1.97$1.63B$10.1312.87

Summary

Regeneron Pharmaceuticals beats Biogen on 14 of the 17 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIIB vs. The Competition

MetricBiogenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.11B$2.88B$5.52B$8.87B
Dividend YieldN/A2.70%5.36%4.13%
P/E Ratio12.8721.3626.4319.81
Price / Sales1.97266.58409.77110.94
Price / Cash5.4641.2925.8827.49
Price / Book1.147.267.945.38
Net Income$1.63B-$55.05M$3.15B$248.34M
7 Day Performance3.21%-0.28%1.15%1.43%
1 Month Performance-0.57%6.80%5.48%5.61%
1 Year Performance-43.75%0.61%33.02%18.27%

Biogen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIIB
Biogen
4.9566 of 5 stars
$129.99
+3.5%
$188.48
+45.0%
-45.8%$19.05B$9.68B12.837,605
REGN
Regeneron Pharmaceuticals
4.936 of 5 stars
$511.66
+0.4%
$836.48
+63.5%
-50.0%$55.24B$14.20B13.0315,106Analyst Downgrade
ALNY
Alnylam Pharmaceuticals
4.2795 of 5 stars
$314.21
+1.5%
$319.58
+1.7%
+34.2%$40.97B$2.25B-150.342,230Positive News
Analyst Forecast
INCY
Incyte
4.3613 of 5 stars
$67.63
-1.2%
$74.53
+10.2%
+12.3%$13.13B$4.24B212.012,617
UTHR
United Therapeutics
4.9948 of 5 stars
$286.02
-1.6%
$393.08
+37.4%
-9.8%$12.90B$2.88B11.411,305Positive News
Analyst Forecast
NBIX
Neurocrine Biosciences
4.9177 of 5 stars
$127.34
+0.6%
$162.00
+27.2%
-8.7%$12.60B$2.36B43.151,800Positive News
EXEL
Exelixis
4.7391 of 5 stars
$43.80
+8.5%
$41.00
-6.4%
+96.2%$11.95B$2.17B19.911,147Positive News
Analyst Forecast
High Trading Volume
BMRN
BioMarin Pharmaceutical
4.9559 of 5 stars
$54.23
-1.4%
$93.45
+72.3%
-33.2%$10.43B$2.95B20.223,040Positive News
EXAS
Exact Sciences
4.8683 of 5 stars
$52.27
-1.4%
$70.90
+35.6%
+25.8%$9.88B$2.76B-9.517,000Positive News
RGEN
Repligen
4.7942 of 5 stars
$117.89
-0.8%
$173.25
+47.0%
-1.3%$6.61B$634.44M-261.561,778Positive News
Analyst Downgrade
HALO
Halozyme Therapeutics
4.8442 of 5 stars
$52.72
-0.2%
$61.90
+17.4%
-0.6%$6.49B$1.02B14.02390Analyst Revision

Related Companies and Tools


This page (NASDAQ:BIIB) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners